文献速递神经核医学

APOE-ε4调节认知正常中年个体局部淀粉样蛋白沉积与认知表现之间的关联

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals.
PubMed 文献 · EJNMMI Res · 2023-03-01

研究纳入352名认知正常中年参与者(平均年龄61.1岁),完成两次认知评估(平均间隔3.34年)、[18F]flutemetamol Aβ PET、T1w MRI及APOE基因分型,以视觉阅读和区域Centiloid评估五个感兴趣区的局部Aβ PET阳性。结果显示全局Aβ PET阳性与APOE-ε4无显著交互作用,但颞区及纹状体视觉阅读阳性的APOE-ε4携带者PACC下降更明显,颞区结果在Centiloid标准下可重复。

要点

  • 全局Aβ PET阳性与APOE-ε4对任何认知测验的认知变化均无显著交互作用。
  • 颞区视觉阅读阳性的APOE-ε4携带者(n=19,9.81%)PACC下降更高(p=0.04)。
  • 纹状体视觉阅读阳性的APOE-ε4携带者(n=8,4.14%)PACC下降更高(p=0.01)。

核心结论

  • 在已知阿尔茨海默病连续谱后期才沉积淀粉样蛋白的脑区,Aβ PET视觉阅读阳性的认知正常APOE-ε4携带者表现出更陡峭的认知下降。
  • 作者认为Aβ PET的局部视觉阅读可能传递关于未来认知下降的预后信息,适用于AD发病风险较高的个体。

研究设计与样本

  • 纳入352名认知正常参与者(平均年龄61.1[4.7]岁),完成两次认知评估(平均间隔3.34年)。
  • 所有参与者接受[18F]flutemetamol Aβ PET、T1w MRI及APOE基因分型。
  • 通过视觉阅读和区域Centiloid评估五个感兴趣区的全局及局部Aβ PET阳性。
  • 采用线性回归模型检验局部及全局Aβ PET阳性与APOE-ε4状态对纵向认知变化的交互作用,并控制年龄、性别、教育、认知基线评分及海马体积。
  • 临床试验注册号:NCT02485730(2015年6月20日注册)和NCT02685969(2016年2月19日注册)。

主要发现

  • 57名参与者(16.2%)为视觉阅读阳性,其中41名(71.9%)为APOE-ε4携带者。
  • 全局Aβ PET阳性与APOE-ε4对任何认知测验的认知变化均无显著交互作用。
  • 颞区视觉阅读阳性的APOE-ε4携带者(n=19[9.81%],p=0.04)PACC下降更高。
  • 纹状体视觉阅读阳性的APOE-ε4携带者(n=8[4.14%],p=0.01)PACC下降更高。
  • 颞区结果在以Centiloid值判定局部PET阳性时可重复;纹状体视觉阅读阳性与更高的记忆下降相关;执行功能方面,APOE-ε4与局部视觉阅读阳性的交互作用见于颞区、顶区及纹状体。

关键数值与推荐

  • 全局及局部Aβ PET阳性通过视觉阅读和区域Centiloid两种方法评估,覆盖五个感兴趣区。
  • 认知变化采用临床前阿尔茨海默病认知复合量表(PACC)、情景记忆和执行功能评估。
  • 颞区视觉阅读阳性与APOE-ε4交互作用对PACC变化的p=0.04(n=19[9.81%])。
  • 纹状体视觉阅读阳性与APOE-ε4交互作用对PACC变化的p=0.01(n=8[4.14%])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether the APOE-ε4 allele modulates the relationship between regional β-amyloid (Aβ) accumulation and cognitive change in middle-aged cognitively unimpaired (CU) participants. METHODS: The 352 CU participants (mean aged 61.1 [4.7] years) included completed two cognitive assessments (average interval 3.34 years), underwent [18F]flutemetamol Aβ positron emission tomography (PET), T1w magnetic resonance imaging (MRI), as well as APOE genotyping. Global and regional Aβ PET positivity was assessed across five regions-of-interest by visual reading (VR) and regional Centiloids. Linear regression models were developed to examine the interaction between regional and global Aβ PET positivity and APOE-ε4 status on longitudinal cognitive change assessed with the Preclinical Alzheimer's Cognitive Composite (PACC), episodic memory, and executive function, after controlling for age, sex, education, cognitive baseline scores, and hippocampal volume. RESULTS: In total, 57 participants (16.2%) were VR+ of whom 41 (71.9%) were APOE-ε4 carriers. No significant APOE-ε4*global Aβ PET interactions were associated with cognitive change for any cognitive test. However, APOE-ε4 carriers who were VR+ in temporal areas (n = 19 [9.81%], p = 0.04) and in the striatum (n = 8 [4.14%], p = 0.01) exhibited a higher decline in the PACC. The temporal areas findings were replicated when regional PET positivity was determined with Centiloid values. Regionally, VR+ in the striatum was associated with higher memory decline. As for executive function, interactions between APOE-ε4 and regional VR+ were found in temporal and parietal regions, and in the striatum. CONCLUSION: CU APOE-ε4 carriers with a positive Aβ PET VR in regions known to accumulate amyloid at later stages of the Alzheimer's disease (AD) continuum exhibited a steeper cognitive decline. This work supports the contention that regional VR of Aβ PET might convey prognostic information about future cognitive decline in individuals at higher risk of developing AD. CLINICALTRIALS: gov Identifier: NCT02485730. Registered 20 June 2015 https://clinicaltrials.gov/ct2/show/NCT02485730 and ClinicalTrials.gov Identifier:NCT02685969. Registered 19 February 2016 https://clinicaltrials.gov/ct2/show/NCT02685969 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Brugulat-Serrat A, Sánchez-Benavides G, Cacciaglia R, et al. APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals. EJNMMI Res. 2023. PMID: 36856866. doi:10.1186/s13550-023-00967-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。